Close Menu

NEW YORK — PharmaCyte Biotech said on Wednesday that it has licensed the rights to SARS-CoV-2 diagnostic technology from Hong Kong-based Hai Kang Life.

According to PharmaCyte, which develops cellular therapies for cancer and diabetes, the deal gives it the right to develop, use, and commercialize kits based on the technology in North America, the UK, and certain undisclosed European markets.

Hai Kang Life said it has developed an enhanced RT-PCR-based method for the detection of SARS-CoV-2 nucleic acid, which it offers at no cost to non-profit health organizations globally.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
18
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Mar
31
Sponsored by
MilliporeSigma

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test. 

Apr
16
Sponsored by
Thermo Fisher Scientific

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.